What the gantenerumab trials teach us about Alzheimer's treatment
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
An amyloid hypothesis1 for Alzheimer’s disease posits that amyloid-beta (Aβ) peptides cleaved from Aβ precursor protein trigger a neurodegenerative cascade, causing cognitive and functional impairment. The peptides have various lengths, ranging from monomers to self-assembled soluble oligomers, insoluble fibrils, and extracellular deposits, or plaques. Any of these species could be toxic. The antiamyloid monoclonal antibodies aducanumab2 and lecanemab3 have been approved by the Food and Drug Administration (FDA) for the treatment of early Alzheimer’s disease; donanemab4 seems to be headed for approval. Aducanumab and lecanemab received accelerated approval on the basis of a reduction in amyloid plaques. Lecanemab later received . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two phase III trials (NCT03444870 and NCT03443973) were recently terminated. In these trials, when assessing the efficacy and safety of gantenerumab (19) in participants with early (prodromal to mild) AD, the drug showed little clinical benefit in slowing cognitive decline, potentially due to limited clearance of amyloid plaques, with 5.0% participants experienced amyloid-related imaging abnormal”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [462]
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Trial of solanezumab in preclinical Alzheimer's disease
Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2305032 · Cited by 429
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359
Two phase 3 trials of gantenerumab in early Alzheimer's disease
Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304430 · Cited by 314
The need to show minimum clinically important differences in Alzheimer's disease trials
Liu, K. Y., Schneider, L. S., & Howard, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00197-8 · Cited by 113
Self-citation
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Self-citationZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Forlenza, O. V., & Barbosa, B. J. A. P. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-e001 · Cited by 22
Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 20
“…and specific selection of eligible patients (i.e., those with a clinical-biological profile more likely to respond to anti-amyloid drugs) and having a better comprehension of the dynamics of treatment outcomes so that clinical trial designs can be adjusted to encompass more realistic endpoints 51 .”
BackgroundRole of Monoclonal Antibodies in Alzheimer’s Disease: Successes, Failures, and Future Directions
Gupta, A., Pahal, S., Kumar, V., & Chaudhary, A. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08456-5 · Cited by 5
“Subsequent Phase III trials were discontinued due to a lack of efficacy, underscoring the complexities of targeting Aβ in AD [ 43, 44].”
Metadata
- Authors
- Schneider, L. S.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Schneider, Lon S.
- ORCID
- Schneider, Lon S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-16
- Volume
- 389
- Issue
- 20
- Pages
- 1918-1920
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388688083
- Cited by
- 6
- References
- 12
- Citations by year
- 2025: 2 · 2024: 4
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- gantenerumab, Alzheimer's disease, amyloid-beta, amyloid hypothesis, anti-amyloid monoclonal antibodies, aducanumab, lecanemab, donanemab, amyloid plaques, accelerated FDA approval, clinical trial results
- MeSH terms
- Alzheimer Disease, Antibodies, Monoclonal, Humans, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What the gantenerumab trials teach us about Alzheimer's treatment. https://app.cochat.ai/papers/10.1056/nejme2310903
- The paper
- Schneider, L. S. (2023). What the gantenerumab trials teach us about Alzheimer's treatment. New England Journal of Medicine. https://doi.org/10.1056/nejme2310903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.